The US Food and Drug Administration (FDA) has announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), despite an appeal by manufacturer Oncopeptides. The drug was originally approved for use in combination with dexamethasone to treat some patients with multiple myeloma. Approval was withdrawn as the confirmatory study conducted as a condition of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!